Targeting the TGFß pathway with galunisertib, a TGFßRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
J Immunother Cancer
; 6(1): 47, 2018 06 04.
Article
en En
| MEDLINE
| ID: mdl-29866156
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Pirazoles
/
Quinolinas
/
Factor de Crecimiento Transformador beta
/
Terapia Combinada
/
Inmunoterapia
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Immunother Cancer
Año:
2018
Tipo del documento:
Article